

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 76958

**Title:** Tislelizumab-related enteritis successfully treated with adalimumab: a case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06257982

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-04-24

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-04-25 11:59

**Reviewer performed review:** 2022-05-04 04:47

**Review time:** 8 Days and 16 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

This case report described the case of a patient developing a tislelizumab-induced enteritis successfully treated with adalimumab (ADA). The degree to which the paper is easy to follow and its logical flow is good. The results are novel, and the study provide an advance in the field.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 76958

**Title:** Tislelizumab-related enteritis successfully treated with adalimumab: a case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03307766

**Position:** Editorial Board

**Academic degree:** MD, MSc, PhD

**Professional title:** Associate Professor, Director, Doctor

**Reviewer's Country/Territory:** Kazakhstan

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-04-24

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-05-05 01:24

**Reviewer performed review:** 2022-05-07 04:11

**Review time:** 2 Days and 2 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

GENERAL - English language needs extensive and careful revision: there are several grammar inconsistencies since the beginning of the manuscript. INTRODUCTION - This section must be definitely expanded. The authors should provide the main concept about the biological treatment of lung cancer and tislelizumab as a biological agent. (see: Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364. doi: 10.1080/13543784.2020.1833857) CASE PRESENTATION - It should be more detailed, especially as regards the main topic of the case report (enteritis). - One or more tables providing a detailed picture of the laboratory parameters are needed. - It is not clear the rational by which the authors used adalimumab - Moreover, HS016 is defined as an adalimumab biosimilar. Was it approved according to the standards of the main drug regulatory agencies (EMA, FDA, WHO) or should it be considered an intended copy? DISCUSSION - To be completely reorganized. It is dispersive and clear points should be discussed. As a consequence, the conclusion is not clear and precise take home messages should be provided. - The authors should point out the wide number of clinical and pathological settings where adalimumab is used, including pediatric and adult disorders (refer to: Bechet disease: Rheumatol Int. 2019 Jun;39(6):1107-1112. doi: 10.1007/s00296-019-04300-0; uveitis: Am J Ophthalmol. 2022 Mar 18:S0002-9394(22)00108-8. doi: 10.1016/j.ajo.2022.03.017; ulcerative colitis: Inflamm Bowel Dis. 2022 Mar 2;28(3):e36-e37. doi: 10.1093/ibd/izab260; etc.)

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 76958

**Title:** Tislelizumab-related enteritis successfully treated with adalimumab: a case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05345731

**Position:** Peer Reviewer

**Academic degree:** BSc, MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Kazakhstan

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-04-24

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-05-06 07:53

**Reviewer performed review:** 2022-05-09 07:58

**Review time:** 3 Days

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

Please correct the grammar again: few points aren't clear like: . "The patient was continued received the treatment of pemetrexed/ carboplatin after symptoms" - the patient continued receiving... "A 61-year-old man The patient was referred to our institution on day 19 after the last treatment for lung cancer, because of symptoms were aggravated, with the frequency of diarrhea up to 20-30 times/day." 61 year-old male patient with Diagnosis...